Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

PHASE3RecruitingINTERVENTIONAL

Enrollment

258

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Jaktinib

Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks

DRUG

Placebo

Participants will receive matching placebo orally twice daily for 16 weeks

Trial Locations (1)

RECRUITING

RenJi Hospital, Shanghai

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY